Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the effect of Sho-saiko-to (Xiao-Chai-Hu-Tang) on HBeAg clearance rate (SN rate) in fourteen children with chronic hepatitis B virus (HBV) infection and with sustained liver disease. Seven of fourteen patients (50.0%) became HBeAg negative in the average observation period of 0.47 years(0.2-0.9 years). Four of those seven patients developed anti-HBe. The annual SN rate in the She-saiko-to treated group was apparently higher than the natural annual SN rate (22.7%) of 22 untreated patients retrospectively reviewed from the onset of hepatitis. Sho-saiko-to seemed to promote clearance of HBeAg in children with chronic HBV infection and with sustained liver disease. Sho-saiko-to may be a useful drug for such patients.
 ...
PMID:Effect of sho-saiko-to(xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. 181 24

The etiology of halothane induced hepatitis is unknown. This study investigated effect of oral administration of Sho-saiko-to on hepatic injury induced by exposure to 1.1% halothane under hypoxic condition (FIO2 = 0.12) for 2 hr in rats. Serum transaminase, histological score and area of necrosis were examined in rats treated with Sho-saiko-to (900 mg.kg-1) before and after halothane exposure. Twenty-four hours following halothane exposure, serum transaminase levels were significantly depressed; the level of sGOT was significantly lower in rats with treatment of Sho-saiko-to (211 +/- 34 IU.l-1) than in rats without treatment (264 +/- 42 IU.l-1) (P less than 0.05), and the level of sGPT was significantly lower in rats with treatment of Sho-saiko-to (144 +/- 20 IU.l-1) than in rats without treatment (215 +/- 46 IU.l-1) (P less than 0.01). Histological score in rats treated with Sho-saiko-to was significantly lower (3.8 +/- 0.6) than in rats without treatment (4.5 +/- 0.7) (P less than 0.05). The area of centrilobular necrosis was significantly lower in rats with treatment of Sho-saiko-to (21.2 +/- 8.7%) than in rats without treatment (34.5 +/- 12.7%) (P less than 0.05), too. These results indicate that Sho-saiko-to inhibits the hepatic necrosis and functional disorder following exposure to halothane.
 ...
PMID:[Effect of sho-saiko-to (xiao-chai-hu-tang) on hepatic injury induced by halothane in rats]. 183 Jan 18

The patient was complicated by type C hepatitis considered dur to blood preparations during the treatment of acute lymphoblastic leukemia. On administration of Sho-saiko-to, the white blood cell count decreased. When the drug was administered again, interstitial pneumonia developed concurrently. The case is a 7-year-old boy. He is the youngest to suffer interstitial pneumonia due to Sho-saiko-to in Japan, showing the possibility that interstitial pneumonia occurs even in childhood. A study of the IgG subclass at the time of the development of interstitial pneumonia in the affected child showed an imbalance of the subclass, with an increase in the percentage of IgG1 and IgG3, and a decreased in the percentage of IgG2 and IgG4. With improvement in the symptoms thereafter, however, the IgG subclass normalized. Thus it is possible that the IgG subclass is concerned with the development of interstitial pneumonia in this case. So, making careful observations is needed in administering Sho saiko-to to children with type C hepatitis who use various immunosuppressants.
 ...
PMID:[Acute lymphoblastic leukemia complicated by type C hepatitis during treatment and further by acute interstitial pneumonia due to sho-saiko-to in 7-year-old]. 943 32

A 71-year-old woman was being treated with Sho-saiko-to for chronic hepatitis. On the 14th day, she complained of dyspnea; chest X-ray films and CT scans revealed ground-glass shadows in both lung fields. Under a suspected diagnosis of drug-induced pneumonia, Sho-saiko-to was discontinued and the patient was started on prednisolone. After several days, her laboratory data and chest X-ray findings were markedly improved. Cell analysis of bronchoalveolar lavage fluid disclosed an increase in the lymphocyte fraction and a depressed CD 4/CD 8 count. Lymphocyte stimulation tests of Sho-saiko-to and its ingredients, Ohgon and Hange, were positive in the case of peripheral lymphocytes, but not bronchoalveolar lavage lymphocytes. These findings yielded a diagnosis of drug-induced pneumonia caused by Sho-saiko-to. A histologic examination of needle biopsy specimens from the liver revealed severe lymphocytic infiltration into the tissues of Glisson's capsule and liver parenchyma, and mild infiltration by plasma cells into tissues surrounding Glisson's capsule. To our knowledge, this is the first case of autoimmune hepatitis with Sho-saiko-to-induced pneumonia to be reported.
 ...
PMID:[Autoimmune hepatitis with drug-induced pneumonia due to Sho-saiko-to]. 1049 5

Oxidative stress has been investigated in the context of alcoholic liver injury for many years and shown to be a causal factor of chronic hepatitis C (CHC), nonalcoholic steatohepatitis (NASH), drug-induced liver injury, Wilson's disease, and hemochromatosis. In CHC, it has been demonstrated that oxidative stress plays an important role in hepatocarcinogenesis. In cases with persistent hepatitis due to failure of hepatitis C virus eradication, or chronic liver disease, such as NASH, the treatment of which remains unestablished, it is important to reduce serum alanine aminotransferase levels and prevent liver fibrosis and development of hepatocellular carcinoma. This also suggests the importance of antioxidant therapy. Among treatment options where it would be expected that anti-inflammatory activity plays a role in their confirmed efficacy for chronic hepatitis, iron depletion therapy, glycyrrhizin, ursodeoxycholic acid, Sho-Saiko-To, and vitamin E can all be considered antioxidant therapies. To date, however, the ability of these treatments to prevent cancer has been confirmed only in CHC. Nevertheless, anti-inflammatory and anti-fibrotic effects have been demonstrated in other liver diseases and these therapies may potentially be effective for cancer prevention.
...
PMID:Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. 2584 83